Skip to main content
SpringerLink
Log in

Statin Intolerance: An Overview for Clinicians

  • Chapter
  • First Online:
Lipoproteins in Diabetes Mellitus

Part of the book series: Contemporary Diabetes ((CDI))

Abstract

Lipid disorders are the most common risk factor for atherosclerotic cardiovascular disease (ASCVD). Statins are the gold standard in the treatment of lipid disorders. These drugs significantly improve the prognosis of patients, both in primary and secondary ASCVD prevention. Statins have a good safety profile, yet they are often not used in the highest tolerated doses and therapy is often discontinued. Some patients may also suffer statin-associated side effects, in most of the cases statin-associated muscle symptoms (SAMSs). The recent data show that the statin intolerance (SI) affects 9.1% of statin users, and, when defined with the approved definitions, even less than 7%. The International Lipid Expert Panel (ILEP) 2015 and 2022 recommendations can be very useful in the management of SI patients. The management of statin intolerance has also been carefully discussed in the Polish guidelines 2021 on diagnosis and management of lipid disorders. Additionally, in the management of statin intolerance, the ILEP position paper on the statin therapy in athletes and patients performing regular exercises can be used. Every effort should be made to disseminate truthful information about statins and to increase patients’ awareness of the benefits of compliance with medical recommendations. The patients need to be well educated about the disease, why the therapy is indicated, and what are the benefits and potential side effects; only for such convinced patients we may have high adherence to statin therapy, which prolongs life, both in primary and secondary cardiovascular prevention.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76:2982–3021.

    Article  PubMed  PubMed Central  Google Scholar 

  2. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Accessed 31 Mar 2022.

  3. Timmis A, Vardas P, Townsend N, et al. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J. 2022;43:716–99.

    Article  PubMed  Google Scholar 

  4. Mortensen MB, Nordestgaard BG. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70–100 years: a contemporary primary prevention cohort. Lancet. 2020;396:1644–52.

    Article  CAS  PubMed  Google Scholar 

  5. Navar-Boggan AM, Peterson ED, D’Agostino RB Sr, Neely B, Sniderman AD, Pencina MJ. Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease. Circulation. 2015;131:451–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Braunwald E. How to live to 100 before developing clinical coronary artery disease: a suggestion. Eur Heart J. 2022;43:249–50.

    Article  PubMed  Google Scholar 

  7. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009;50(Suppl):172–7.

    Article  Google Scholar 

  8. Bianconi V, Banach M, Pirro M. Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels. Trends Cardiovasc Med. 2021;31:205–15.

    Article  CAS  PubMed  Google Scholar 

  9. Surma S, Rakowski M, Banach M. The role of high doses of atorvastatin or rosuvastatin in the treatment of cardiovascular diseases. Świat Medycyny i Farmacji. 2021;11/12:10–21. [article in Polish, only abstract in English]

    Google Scholar 

  10. Banach M, Burchardt P, Chlebus K, et al. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci. 2021;17:1447–547.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Catapano AL, Farnier M, Foody JM, et al. Combination therapy in dyslipidemia: where are we now? Atherosclerosis. 2014;237:319–35.

    Article  CAS  PubMed  Google Scholar 

  12. Banach M, Penson PE, Vrablik M, et al. ACS EuroPath Central & South European Countries Project Optimal use of lipid-lowering therapy after acute coronary syndromes: a position paper endorsed by the International Lipid Expert Panel (ILEP). Pharmacol Res. 2021;166:105499.

    Article  CAS  PubMed  Google Scholar 

  13. Penson PE, Pirro M, Banach M. LDL-C: lower is better for longer-even at low risk. BMC Med. 2020;18:320.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Ray KK, Reeskamp LF, Laufs U, et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2022;43:830–3.

    Article  CAS  PubMed  Google Scholar 

  15. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA. 2018;319:1566–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Ma W, Pan Q, Pan D, et al. Efficacy and safety of lipid-lowering drugs of different intensity on clinical outcomes: a systematic review and network meta-analysis. Front Pharmacol. 2021;12:713007.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Dyrbuś K, Gąsior M, Penson PE, Banach M. Extreme cardiovascular risk-do we need a new risk category? Eur Heart J. 2022;43(19):1784–6.

    Article  PubMed  Google Scholar 

  18. Ward NC, Watts GF, Eckel RH. Statin toxicity. Circ Res. 2019;124:328–50.

    Article  CAS  PubMed  Google Scholar 

  19. Egom EE, Hafeez H. Biochemistry of statins. Adv Clin Chem. 2016;73:127–68.

    Article  CAS  PubMed  Google Scholar 

  20. Murphy C, Deplazes E, Cranfield CG, Garcia A. The role of structure and biophysical properties in the pleiotropic effects of statins. Int J Mol Sci. 2020;21:8745.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Feingold KR. Cholesterol lowering drugs [Updated 2021 Mar 30]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth, MA: MD Text.com, Inc.; 2000.

    Google Scholar 

  22. Teramoto T, Watkins C. Review of efficacy of rosuvastatin 5 mg. Int J Clin Pract. 2005;59:92–101.

    Article  CAS  PubMed  Google Scholar 

  23. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92:152–60.

    Article  CAS  PubMed  Google Scholar 

  24. Adams SP, Alaeiilkhchi N, Wright JM. Pitavastatin for lowering lipids. Cochrane Database Syst Rev. 2020;6:CD012735.

    PubMed  Google Scholar 

  25. Zhang X, Xing L, Jia X, et al. Comparative lipid-lowering/increasing efficacy of 7 statins in patients with dyslipidemia, cardiovascular diseases, or diabetes mellitus: systematic review and network meta-analyses of 50 randomized controlled trials. Cardiovasc Ther. 2020;2020:3987065.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: a systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. Am Heart J. 2019;210:18–28.

    Article  CAS  PubMed  Google Scholar 

  27. Tramacere I, Boncoraglio GB, Banzi R, et al. Comparison of statins for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis. BMC Med. 2019;17:67.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Yu S, Jin J, Chen Z, Luo X. High-intensity statin therapy yields better outcomes in acute coronary syndrome patients: a meta-analysis involving 26,497 patients. Lipids Health Dis. 2020;19:194.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. de Vries FM, Kolthof J, Postma MJ, Denig P, Hak E. Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: a meta-analysis. PLoS One. 2014;9:e111247.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Koskinas KC, Siontis GCM, Piccolo R, et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J. 2018;39:1172–80.

    Article  CAS  PubMed  Google Scholar 

  31. Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM. 2011;104:109–24.

    Article  CAS  PubMed  Google Scholar 

  32. Fulcher J, O’Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385:1397–405.

    Article  PubMed  Google Scholar 

  33. Blais JE, Wei Y, Yap KKW, et al. Trends in lipid-modifying agent use in 83 countries. Atherosclerosis. 2021;328:44–51.

    Article  CAS  PubMed  Google Scholar 

  34. Surma S, Banach M, Lewek J. COVID-19 and lipids. The role of lipid disorders and statin use in the prognosis of patients with SARS-CoV-2 infection. Lipids Health Dis. 2021;20:141.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Katsiki N, Banach M, Mikhailidis DP. More good news on statins and COVID-19. Am J Cardiol. 2021;138:127–8.

    Article  CAS  PubMed  Google Scholar 

  36. Vahedian-Azimi A, Mohammadi SM, Banach M, et al. Improved COVID-19 outcomes following statin therapy: an updated systematic review and meta-analysis. Biomed Res Int. 2021;2021:1901772.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Banach M, Penson PE, Fras Z, et al. Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic. Pharmacol Res. 2020;158:104891.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Banach M, Rizzo M, Toth PP, et al. Statin intolerance—an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015;11:1–23.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Cai T, Abel L, Langford O, et al. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ. 2021;374:n1537.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403–14.

    Article  CAS  PubMed  Google Scholar 

  41. Taguchi I, Iimuro S, Iwata H, et al. High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD): a randomized superiority trial. Circulation. 2018;137:1997–2009. Erratum in: Circulation. 2019;139:e836

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Bytyçi I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;43(34):3213–23.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Navar AM, Peterson ED, Li S, et al. Prevalence and management of symptoms associated with statin therapy in community practice: insights from the PALM (Patient and Provider Assessment of Lipid Management) registry. Circ Cardiovasc Qual Outcomes. 2018;11:e004249.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Davis JW, Weller SC. Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients. BMJ Open. 2021;11:e043714.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Riaz H, Khan AR, Khan MS, et al. Meta-analysis of placebo-controlled randomized controlled trials on the prevalence of statin intolerance. Am J Cardiol. 2017;120:774–81.

    Article  CAS  PubMed  Google Scholar 

  46. Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes. 2013;6:390–9.

    Article  PubMed  Google Scholar 

  47. Herrett E, Williamson E, Brack K, et al. The effect of statins on muscle symptoms in primary care: the StatinWISE series of 200 N-of-1 RCTs. Health Technol Assess. 2021;25:1–62.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39:38–81.

    Article  Google Scholar 

  49. Vinci P, Panizon E, Tosoni LM, et al. Statin-associated myopathy: emphasis on mechanisms and targeted therapy. Int J Mol Sci. 2021;22:11687.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Xiang Q, Zhang XD, Mu GY, et al. Correlation between single-nucleotide polymorphisms and statin-induced myopathy: a mixed-effects model meta-analysis. Eur J Clin Pharmacol. 2021;77:569–81.

    Article  CAS  PubMed  Google Scholar 

  51. Ruscica M, Ferri N, Banach M, Sirtori CR, Corsini A. Side effects of statins-from pathophysiology and epidemiology to diagnostic and therapeutic implications. Cardiovasc Res. 2022;118(17):3288–304.

    Article  Google Scholar 

  52. Yang J, Zhou J, Wang X, et al. Risk factors for severe acute kidney injury among patients with rhabdomyolysis. BMC Nephrol. 2020;21:498.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Safitri N, Alaina MF, Pitaloka DAE, Abdulah R. A narrative review of statin-induced rhabdomyolysis: molecular mechanism, risk factors, and management. Drug Healthc Patient Saf. 2021;13:211–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Nikolic D, Banach M, Nikfar S, Lipid and Blood Pressure Meta-Analysis Collaboration Group, et al. A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important? Int J Cardiol. 2013;168:5437–47.

    Article  PubMed  Google Scholar 

  55. Zhao L, Li S, Gao Y. Efficacy of statins on renal function in patients with chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2021;43:718–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Mansouri A, Reiner Ž, Ruscica M, et al. Antioxidant effects of statins by modulating Nrf2 and Nrf2/HO-1 signaling in different diseases. J Clin Med. 2022;11:1313.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Lv J, Ren C, Hu Q. Effect of statins on the treatment of early diabetic nephropathy: a systematic review and meta-analysis of nine randomized controlled trials. Ann Palliat Med. 2021;10:11548–57.

    Article  PubMed  Google Scholar 

  58. Barylski M, Nikfar S, Mikhailidis DP, Lipid and Blood Pressure Meta-Analysis Collaboration Group, et al. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy—a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res. 2013;72:35–44.

    Article  CAS  PubMed  Google Scholar 

  59. Liang X, He Q, Zhao Q. Effect of stains on LDL reduction and liver safety: a systematic review and meta-analysis. Biomed Res Int. 2018;2018:7092414.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Masson W, Lobo M, Masson G, Molinero G, Casciato P. Statin use in patients with elevated serum hepatic transaminases at baseline: a meta-analysis. Nutr Metab Cardiovasc Dis. 2021;31:1357–64.

    Article  CAS  PubMed  Google Scholar 

  61. Vahedian-Azimi A, Shojaie S, Banach M, et al. Statin therapy in chronic viral hepatitis: a systematic review and meta-analysis of nine studies with 195,602 participants. Ann Med. 2021;53:1227–42.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Kim RG, Loomba R, Prokop LJ, Singh S. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15:1521–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Fatima K, Moeed A, Waqar E, et al. Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2021;46:101816.

    Article  PubMed  Google Scholar 

  64. Pastori D, Pani A, Di Rocco A, et al. Statin liver safety in non-alcoholic fatty liver disease: a systematic review and metanalysis. Br J Clin Pharmacol. 2022;88:441–51.

    Article  CAS  PubMed  Google Scholar 

  65. Wang CH, Huang CW, Nguyen PA, et al. Chemopreventive effects of concomitant or individual use of statins, aspirin, metformin, and angiotensin drugs: a study using claims data of 23 million individuals. Cancers (Basel). 2022;14:1211.

    Article  CAS  PubMed  Google Scholar 

  66. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556–64.

    Article  CAS  PubMed  Google Scholar 

  67. Thakker D, Nair S, Pagada A, Jamdade V, Malik A. Statin use and the risk of developing diabetes: a network meta-analysis. Pharmacoepidemiol Drug Saf. 2016;25:1131–49.

    Article  CAS  PubMed  Google Scholar 

  68. Navarese EP, Buffon A, Andreotti F, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol. 2013;111:1123–30.

    Article  CAS  PubMed  Google Scholar 

  69. Kamran H, Kupferstein E, Sharma N, et al. Statins and new-onset diabetes in cardiovascular and kidney disease cohorts: a meta-analysis. Cardiorenal Med. 2018;8:105–12.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Danaei G, García Rodríguez LA, Fernandez Cantero O, Hernán MA. Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival. Diabetes Care. 2013;36:1236–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Savarese G, Gotto AM Jr, Paolillo S, et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J Am Coll Cardiol. 2013;62:2090–9.

    Article  CAS  PubMed  Google Scholar 

  72. Teng M, Lin L, Zhao YJ, et al. Statins for primary prevention of cardiovascular disease in elderly patients: systematic review and meta-analysis. Drugs Aging. 2015;32:649–61.

    Article  CAS  PubMed  Google Scholar 

  73. Kostis JB, Giakoumis M, Zinonos S, Cabrera J, Kostis WJ. Meta-analysis of usefulness of treatment of hypercholesterolemia with statins for primary prevention in patients older than 75 years. Am J Cardiol. 2020;125:1154–7.

    Article  PubMed  Google Scholar 

  74. Ponce OJ, Larrea-Mantilla L, Hemmingsen B, et al. Lipid-lowering agents in older individuals: a systematic review and meta-analysis of randomized clinical trials. J Clin Endocrinol Metab. 2019;104:1585–94.

    Article  PubMed  Google Scholar 

  75. Armitage J, Baigent C, Barnes E, et al. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393:407–15.

    Article  Google Scholar 

  76. Awad K, Mohammed M, Zaki MM, et al. Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies. BMC Med. 2021;19:139.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Zhou Z, Albarqouni L, Curtis AJ, Breslin M, Nelson M. The safety and tolerability of statin therapy in primary prevention in older adults: a systematic review and meta-analysis. Drugs Aging. 2020;37:175–85.

    Article  CAS  PubMed  Google Scholar 

  78. Ott BR, Daiello LA, Dahabreh IJ, et al. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med. 2015;30:348–58.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Chu CS, Tseng PT, Stubbs B, et al. Use of statins and the risk of dementia and mild cognitive impairment: a systematic review and meta-analysis. Sci Rep. 2018;8:5804.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5:133–40.

    Article  PubMed  Google Scholar 

  81. Luirink IK, Wiegman A, Kusters DM, et al. 20-Year follow-up of statins in children with familial hypercholesterolemia. N Engl J Med. 2019;381:1547–56.

    Article  CAS  PubMed  Google Scholar 

  82. Peterson AL, McNeal CJ, Wilson DP. Prevention of atherosclerotic cardiovascular disease in children with familial hypercholesterolemia. Curr Atheroscler Rep. 2021;23:64.

    Article  PubMed  Google Scholar 

  83. Kavey RW, Manlhiot C, Runeckles K, et al. Effectiveness and safety of statin therapy in children: a real-world clinical practice experience. CJC Open. 2020;2:473–82.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Anagnostis P, Vaitsi K, Kleitsioti P, et al. Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized-controlled trials. Endocrine. 2020;69:249–61.

    Article  CAS  PubMed  Google Scholar 

  85. Podgórski M, Szatko K, Stańczyk M, et al. “Apple does not fall far from the tree”—subclinical atherosclerosis in children with familial hypercholesterolemia. Lipids Health Dis. 2020;19:169.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Lewek J, Konopka A, Starostecka E, Penson PE, Maciejewski M, Banach M. Clinical features of familial hypercholesterolemia in children and adults in EAS-FHSC regional center for rare diseases in Poland. J Clin Med. 2021;10:4302.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Bjelakovic B, Stefanutti C, Reiner Ž, et al. Risk assessment and clinical management of children and adolescents with heterozygous familial hypercholesterolaemia. A position paper of the Associations of Preventive Pediatrics of Serbia, Mighty Medic and International Lipid Expert Panel. J Clin Med. 2021;10:4930.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Vahedian-Azimi A, Bianconi V, Makvandi S, et al. A systematic review and meta-analysis on the effects of statins on pregnancy outcomes. Atherosclerosis. 2021;336:1–11.

    Article  CAS  PubMed  Google Scholar 

  89. Vahedian-Azimi A, Karimi L, Reiner Ž, Makvandi S, Sahebkar A. Effects of statins on preeclampsia: a systematic review. Pregnancy Hypertens. 2021;23:123–30.

    Article  PubMed  Google Scholar 

  90. Vahedian-Azimi A, Makvandi S, Banach M, Reiner Ž, Sahebkar A. Fetal toxicity associated with statins: a systematic review and meta-analysis. Atherosclerosis. 2021;327:59–67.

    Article  CAS  PubMed  Google Scholar 

  91. Banach M, Jankowski P, Jóźwiak J, et al. PoLA/CFPiP/PCS guidelines for the management of dyslipidaemias for family physicians 2016. Arch Med Sci. 2017;13:1–45.

    Article  PubMed  Google Scholar 

  92. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1—Executive summary. J Clin Lipidol. 2014;8:473–88.

    Article  PubMed  Google Scholar 

  93. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36:1012–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group Update (2016). Can J Cardiol. 2016;32:35–65.

    Article  Google Scholar 

  95. Sposito AC, Faria Neto JR, Carvalho LS, Lorenzatti A, Cafferata A, Elikir G, et al. Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium. Curr Med Res Opin. 2017;33:239–51.

    Article  CAS  PubMed  Google Scholar 

  96. Ray KK, Molemans B, Schoonen WM, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DAVINCI study. Eur J Prev Cardiol. 2021;28:1279–89.

    Article  PubMed  Google Scholar 

  97. Vrablik M, Seifert B, Parkhomenko A, et al. Are risk-based LDL-C goals achieved in primary and secondary care in Central and Eastern Europe? Comparison with other Europe regions from the DA VINCI observational study. Atherosclerosis. 2021;334:66–75.

    Article  CAS  PubMed  Google Scholar 

  98. Hope HF, Binkley GM, Fenton S, et al. Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease. PLoS One. 2019;14:e0201196.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Bradley CK, Wang TY, Li S, et al. Patient-reported reasons for declining or discontinuing statin therapy: insights from the PALM registry. J Am Heart Assoc. 2019;8:e011765.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Huber D, Wikén C, Henriksson R, Söderström L, Mooe T. Statin treatment after acute coronary syndrome: adherence and reasons for non-adherence in a randomized controlled intervention trial. Sci Rep. 2021;11:6454.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Giral P, Neumann A, Weill A, Coste J. Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France. Eur Heart J. 2019;40:3516–25.

    Article  PubMed  PubMed Central  Google Scholar 

  102. Sigglekow F, Horsburgh S, Parkin L. Statin adherence is lower in primary than secondary prevention: a national follow-up study of new users. PLoS One. 2020;15:e0242424.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Vinogradova Y, Coupland C, Brindle P, Hippisley-Cox J. Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database. BMJ. 2016;353:i3305.

    Article  PubMed  PubMed Central  Google Scholar 

  104. Rezende Macedo do Nascimento RC, Mueller T, Godman B, et al. Real-world evaluation of the impact of statin intensity on adherence and persistence to therapy: a Scottish population-based study. Br J Clin Pharmacol. 2020;86:2349–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Booth JN III, Colantonio LD, Chen L, et al. Statin discontinuation, reinitiation, and persistence patterns among medicare beneficiaries after myocardial infarction: a cohort study. Circ Cardiovasc Qual Outcomes. 2017;10:e003626.

    Article  PubMed  Google Scholar 

  106. Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2019;4:206–13.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Colantonio LD, Huang L, Monda KL, et al. Adherence to high-intensity statins following a myocardial infarction hospitalization among Medicare beneficiaries. JAMA Cardiol. 2017;2:890–5.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44:1410–21.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Ofori-Asenso R, Jakhu A, Zomer E, et al. Adherence and persistence among statin users aged 65 years and over: a systematic review and meta-analysis. J Gerontol A Biol Sci Med Sci. 2018;73:813–9.

    Article  PubMed  Google Scholar 

  110. Lemstra M, Blackburn D, Crawley A, Fung R. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol. 2012;28:574–80.

    Article  PubMed  Google Scholar 

  111. Ingersgaard MV, Helms Andersen T, Norgaard O, Grabowski D, Olesen K. Reasons for nonadherence to statins—a systematic review of reviews. Patient Prefer Adherence. 2020;14:675–91.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Wouters H, Van Dijk L, Geers HC, et al. Understanding statin non-adherence: knowing which perceptions and experiences matter to different patients. PLoS One. 2016;11:e0146272.

    Article  PubMed  PubMed Central  Google Scholar 

  113. Penson PE, Banach M. Nocebo/drucebo effect in statin-intolerant patients: an attempt at recommendations. Eur Heart J. 2021;42:4787–8.

    Article  PubMed  Google Scholar 

  114. Tarn DM, Pletcher MJ, Tosqui R, et al. Primary nonadherence to statin medications: survey of patient perspectives. Prev Med Rep. 2021;22:101357.

    Article  PubMed  PubMed Central  Google Scholar 

  115. Penson PE, Bruckert E, Marais D, et al. Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). J Cachexia Sarcopenia Muscle. 2022;13(3):1596–622.

    Article  PubMed  PubMed Central  Google Scholar 

  116. Matthews A, Herrett E, Gasparrini A, et al. Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data. BMJ. 2016;353:i3283.

    Article  PubMed  PubMed Central  Google Scholar 

  117. Nelson AJ, Puri R, Nissen SE. Statins in a distorted mirror of media. Curr Atheroscler Rep. 2020;22:37.

    Article  PubMed  Google Scholar 

  118. Golder S, O’Connor K, Hennessy S, Gross R, Gonzalez-Hernandez G. Assessment of beliefs and attitudes about statins posted on Twitter: a qualitative study. JAMA Netw Open. 2020;3:e208953.

    Article  PubMed  PubMed Central  Google Scholar 

  119. Jones NM, Mukamel DB, Malik S, et al. The costs outweigh the benefits: seeing side-effects online may decrease adherence to statins. BMC Med Inform Decis Mak. 2020;20:197.

    Article  PubMed  PubMed Central  Google Scholar 

  120. Scherer LD, McPhetres J, Pennycook G, et al. Who is susceptible to online health misinformation? A test of four psychosocial hypotheses. Health Psychol. 2021;40:274–84.

    Article  PubMed  Google Scholar 

  121. Treharne T, Papanikitas A. Defining and detecting fake news in health and medicine reporting. J R Soc Med. 2020;113:302–5.

    Article  PubMed  PubMed Central  Google Scholar 

  122. Lansberg P, Lee A, Lee ZV, Subramaniam K, Setia S. Nonadherence to statins: individualized intervention strategies outside the pill box. Vasc Health Risk Manag. 2018;14:91–102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Thompson W, Morin L, Jarbøl DE, et al. Statin discontinuation and cardiovascular events among older people in Denmark. JAMA Netw Open. 2021;4:e2136802.

    Article  PubMed  PubMed Central  Google Scholar 

  124. Rea F, Biffi A, Ronco R, et al. Cardiovascular outcomes and mortality associated with discontinuing statins in older patients receiving polypharmacy. JAMA Netw Open. 2021;4:e2113186.

    Article  PubMed  PubMed Central  Google Scholar 

  125. Rannanheimo PK, Tiittanen P, Hartikainen J, et al. Impact of statin adherence on cardiovascular morbidity and all-cause mortality in the primary prevention of cardiovascular disease: a population-based cohort study in Finland. Value Health. 2015;18:896–905.

    Article  PubMed  Google Scholar 

  126. Serban MC, Colantonio LD, Manthripragada AD, et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol. 2017;69:1386–95.

    Article  CAS  PubMed  Google Scholar 

  127. Martin-Ruiz E, Olry-de-Labry-Lima A, Ocaña-Riola R, Epstein D. Systematic review of the effect of adherence to statin treatment on critical cardiovascular events and mortality in primary prevention. J Cardiovasc Pharmacol Ther. 2018;23:200–15.

    Article  CAS  PubMed  Google Scholar 

  128. Kolte D, Aronow WS, Banach M. Polypills for the prevention of cardiovascular diseases. Expert Opin Investig Drugs. 2016;25:1255–64.

    Article  CAS  PubMed  Google Scholar 

  129. Rea F, Savaré L, Corrao G, Mancia G. Adherence to lipid-lowering treatment by single-pill combination of statin and ezetimibe. Adv Ther. 2021;38:5270–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Lafeber M, Grobbee DE, Schrover IM, et al. Comparison of a morning polypill, evening polypill and individual pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk patients; a randomized crossover trial. Int J Cardiol. 2015;181:193–9.

    Article  CAS  PubMed  Google Scholar 

  131. Parati G, Kjeldsen S, Coca A, Cushman WC, Wang J. Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis. Hypertension. 2021;77:692–705.

    Article  CAS  PubMed  Google Scholar 

  132. Katsiki N, Mikhailidis DP, Bajraktari G, et al. Statin therapy in athletes and patients performing regular intense exercise—position paper from the International Lipid Expert Panel (ILEP). Pharmacol Res. 2020;155:104719.

    Article  CAS  PubMed  Google Scholar 

  133. Penson PE, Mancini GBJ, Toth PP, et al. Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. J Cachexia Sarcopenia Muscle. 2018;9:1023–33.

    Article  PubMed  PubMed Central  Google Scholar 

  134. Rosenson RS, Baker S, Banach M, et al. Optimizing cholesterol treatment in patients with muscle complaints. J Am Coll Cardiol. 2017;70:1290–301.

    Article  PubMed  Google Scholar 

  135. Toth PP, Patti AM, Giglio RV, Nikolic D, Castellino G, Rizzo M, Banach M. Management of statin intolerance in 2018: still more questions than answers. Am J Cardiovasc Drugs. 2018;18:157–73.

    Article  PubMed  PubMed Central  Google Scholar 

  136. Patel J, Martin SS, Banach M. Expert opinion: the therapeutic challenges faced by statin intolerance. Expert Opin Pharmacother. 2016;17:1497–507.

    Article  CAS  PubMed  Google Scholar 

  137. Awad K, Mikhailidis DP, Toth PP, Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group, et al. Efficacy and safety of alternate-day versus daily dosing of statins: a systematic review and meta-analysis. Cardiovasc Drugs Ther. 2017;31:419–31.

    Article  CAS  PubMed  Google Scholar 

  138. Banach M, Patti AM, Giglio RV, International Lipid Expert Panel (ILEP), et al. The role of nutraceuticals in statin intolerant patients. J Am Coll Cardiol. 2018;72:96–118.

    Article  PubMed  Google Scholar 

  139. Cicero AFG, Colletti A, Bajraktari G, et al. Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Arch Med Sci. 2017;13:965–1005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  140. Sahebkar A, Saboni N, Pirro M, Banach M. Curcumin: an effective adjunct in patients with statin-associated muscle symptoms? J Cachexia Sarcopenia Muscle. 2017;8:19–24.

    Article  PubMed  Google Scholar 

  141. Jeong HS, Hong SJ, Son S, et al. Incidence of new-onset diabetes with 1 mg versus 4 mg pitavastatin in patients at high risk of developing diabetes during a 3-year follow-up. Cardiovasc Diabetol. 2019;18:162.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  142. Liu WT, Lin C, Tsai MC, et al. Effects of pitavastatin, atorvastatin, and rosuvastatin on the risk of new-onset diabetes mellitus: a single-center cohort study. Biomedicine. 2020;8:499.

    CAS  Google Scholar 

  143. Rosenson RS, Miller K, Bayliss M, et al. The statin-associated muscle symptom clinical index (SAMS-CI): revision for clinical use, content validation, and interrater reliability. Cardiovasc Drugs Ther. 2017;31:179–86.

    Article  PubMed  PubMed Central  Google Scholar 

  144. Banach M. Statin intolerance—we know everything, we know nothing. J Clin Med. 2022;11:5250.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

  1. Stanisław Surma and Joanna Lewek contributed equally with all other contributors.

Authors and Affiliations

  1. Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland

    Stanisław Surma

  2. Club of Young Hypertensiologists, Polish Society of Hypertension, Gdansk, Poland

    Stanisław Surma

  3. Polish Lipid Association (PLA), Lodz, Poland

    Stanisław Surma, Joanna Lewek & Maciej Banach

  4. Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland

    Joanna Lewek & Maciej Banach

  5. Department of Cardiology and Adult Congenital Heart Diseases, Polish Mother’s Memorial Hospital Research Institute (PMMHRI), Lodz, Poland

    Joanna Lewek & Maciej Banach

  6. School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK

    Peter E. Penson

  7. Liverpool Centre for Cardiovascular Science, Liverpool, UK

    Peter E. Penson

  8. Cardiovascular Research Centre, University of Zielona Góra, Zielona Góra, Poland

    Maciej Banach

Authors
  1. Stanisław Surma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joanna Lewek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter E. Penson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maciej Banach
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maciej Banach .

Editor information

Editors and Affiliations

  1. NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia

    Alicia J. Jenkins

  2. Department of Medicine, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Peter P. Toth

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Surma, S., Lewek, J., Penson, P.E., Banach, M. (2023). Statin Intolerance: An Overview for Clinicians. In: Jenkins, A.J., Toth, P.P. (eds) Lipoproteins in Diabetes Mellitus. Contemporary Diabetes. Humana, Cham. https://doi.org/10.1007/978-3-031-26681-2_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-26681-2_23

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-031-26680-5

  • Online ISBN: 978-3-031-26681-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation